Combination therapy in 2020 among Schedule II stimulant users
| Combination-2* | Combination-3† | |||
| Yes | No | Yes | No | |
| No (%) | No (%) | No (%) | No (%) | |
| All users | 125 781 (45.5) | 150 442 (54.5) | 66 996 (24.3) | 209 227 (75.7) |
| Gender | ||||
| Male | 43 225 (36.2) | 76 046 (63.8) | 20 708 (17.4) | 98 563 (82.6) |
| Female | 82 556 (52.6) | 74 396 (47.4) | 46 288 (29.5) | 110 664 (70.5) |
| Age group (years) | ||||
| 19–34 | 44 549 (34.7) | 83 708 (65.3) | 20 371 (15.9) | 107 886 (84.1) |
| 35–44 | 32 608 (49.1) | 33 779 (50.9) | 17 277 (26.0) | 49 110 (74.0) |
| 45–54 | 29 708 (57.5) | 21 950 (42.5) | 17 452 (33.8) | 34 206 (66.2) |
| 55–64 | 18 916 (63.2) | 11 005 (36.8) | 11 896 (39.8) | 18 025 (60.2) |
| Exposure pattern, median (IQR) | ||||
| Stimulant treatment days | 271(179–335) | 173(60–300) | 283 (194–338) | 202 (90–313) |
| Combination therapy days | 213 (126–301) | 0 (0–5) | 182 (108–276) | 0 (0–4) |
| Non-stimulant CNS prescriptions | 11 (6–20) | 0 (0–1) | 18 (12–27) | 1 (0–5) |
Source: MarketScan Research Databases, 2019–2020, commercially insured adults, age 19–64 years. Schedule II stimulants include amphetamine and methylphenidate drug products.
*≥60 days’ use of stimulant+at least one other CNS-active drug.
†≥60 days’ use of stimulant+at least two other CNS-active drugs.
CNS, central nervous system.